Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the efficacy of lumiracoxib in primary hip osteoarthritis by testing the hypotheses that lumiracoxib 100 mg o.d. is superior to placebo with respect to the pain sub-scale of the WOMAC 3.1LK questionnaire, the difficulty performing daily activities (DPDA) sub-scale of the WOMAC 3.1LK questionnaire, and patient's global assessment of disease activity on a 100 mm VAS after 13 weeks of treatment
Critère d'inclusion
- Primary osteoarthritis of the hip